CRO giant Pharmaceutical Product Development LLC terminated a number of employees in its human resources department, but has provided few details about the job cuts, according to reports.
W2O Group, a network of innovative analytics-driven, digital-first marketing and communications firms, announced the appointment of three senior executives in its growing Chicago office.
GlaxoSmithKline poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head.
Omnicom Health Group announced that Mario Muredda has been named CEO of Harrison and Star and former CEO Ty Curran has been promoted to chairman. The changes are effective January 1, 2018.
Omnicom Health Group announced that Kirsten A. Kantak was appointed CEO of Biolumina.
X-Spine Systems, a division of Xtant Medical Systems, is shutting down a facility in Ohio and terminating 54 people between December and February 2018.
As part of a new sales team structure, Merck plans to cut 1,800 sales jobs. At the same time, the company expects to add 960 jobs to a new sales force focused on chronic care.
Switzerland-based Novartis is closing the company’s generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.
An investor decision to renege on acquiring more than $3 million worth of stock has created a financial catastrophe for Biostage Inc. To maintain operations, the company is terminating 17 employees, about 71 percent of its workforce.
Two months after slashing 28 percent of its workforce as part of a strategic review, Ardelyx Inc. announced positive Phase III results for tenapanor, its irritable bowel syndrome with constipation (IBS-C).